Literature DB >> 25079172

The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma.

E Kastritis1, L A Moulopoulos2, E Terpos1, V Koutoulidis2, M A Dimopoulos1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25079172     DOI： 10.1038/leu.2014.230

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

2.  Diagnosis of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Dirk Larson; Robert A Kyle
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

3.  Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.

Authors:  L A Moulopoulos; D Gika; A Anagnostopoulos; K Delasalle; D Weber; R Alexanian; M A Dimopoulos
Journal:  Ann Oncol       Date:  2005-08-08       Impact factor: 32.976

4.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

Review 5.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

6.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

7.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

Review 8.  Smoldering multiple myeloma requiring treatment: time for a new definition?

Authors:  Angela Dispenzieri; A Keith Stewart; Asher Chanan-Khan; S Vincent Rajkumar; Robert A Kyle; Rafael Fonseca; Prashant Kapoor; P Leif Bergsagel; Arleigh McCurdy; Morie A Gertz; Martha Q Lacy; John A Lust; Stephen J Russell; Steven R Zeldenrust; Craig Reeder; Vivek Roy; Francis Buadi; David Dingli; Suzanne R Hayman; Nelson Leung; Yi Lin; Joseph Mikhael; Shaji K Kumar
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

9.  Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  L A Moulopoulos; M A Dimopoulos; T L Smith; D M Weber; K B Delasalle; H I Libshitz; R Alexanian
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

10.  Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.

Authors:  E Kastritis; E Terpos; L Moulopoulos; M Spyropoulou-Vlachou; N Kanellias; E Eleftherakis-Papaiakovou; M Gkotzamanidou; M Migkou; M Gavriatopoulou; M Roussou; A Tasidou; M A Dimopoulos
Journal:  Leukemia       Date:  2012-11-06       Impact factor: 11.528
View more
  26 in total

Review 1.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

Review 2.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Authors:  Chutima Kunacheewa; Elisabet E Manasanch
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-25       Impact factor: 3.020

Review 4.  The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Authors:  Jo Caers; Carlos Fernández de Larrea; Xavier Leleu; Roy Heusschen; Niklas Zojer; Olivier Decaux; Efstathios Kastritis; Monique Minnema; Artur Jurczyszyn; Yves Beguin; Ralph Wäsch; Antonio Palumbo; Meletios Dimopoulos; Maria Victoria Mateos; Heinz Ludwig; Monika Engelhardt
Journal:  Oncologist       Date:  2016-02-26

Review 5.  Diagnostic Advances in Multiple Myeloma.

Authors:  Kevin Barley; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

6.  European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Authors:  Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 7.  Shall we treat smoldering multiple myeloma in the near future?

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 8.  Functional and molecular MRI of the bone marrow in multiple myeloma.

Authors:  Vassilis Koutoulidis; Nickolas Papanikolaou; Lia A Moulopoulos
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

9.  [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Authors:  S C Brandelik; J Krzykalla; T Hielscher; J Hillengass; J K Kloth; H U Kauczor; M A Weber
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

10.  Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.

Authors:  W I Gonsalves; S V Rajkumar; A Dispenzieri; D Dingli; M M Timm; W G Morice; M Q Lacy; F K Buadi; R S Go; N Leung; P Kapoor; S R Hayman; J A Lust; S J Russell; S R Zeldenrust; L Hwa; T V Kourelis; R A Kyle; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2016-07-26       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.